P1513: REDUCTION OF THE PROPHYLACTIC EFFECT OF TIXAGEVIMAB-CILGAVIMAB IN THE OMICRON ERA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND WITHOUT ANTIBODY RESPONSE FOLLOWING SARS-COV-2 VACCINATION.

• Chiara Callegari,
• Martina Mutti,
• Alessandra Soravia,
• Pietro Lauzzana,
• Davide Lazzarotto,
• Maddalena Peghin,
• Stefano Cordella,
• Renato Fanin,
• Anna Candoni

Affiliations

Chiara Callegari

1 Division of Hematology, Azienda Sanitaria-Universitaria Friuli Centrale, ASUFC, Udine, Italy

Martina Mutti

2 Division of Hematology, University of Modena and Reggio Emilia, Dept. of Medical and Surgical Sciences, Modena, Italy

Alessandra Soravia

1 Division of Hematology, Azienda Sanitaria-Universitaria Friuli Centrale, ASUFC, Udine, Italy

Pietro Lauzzana

1 Division of Hematology, Azienda Sanitaria-Universitaria Friuli Centrale, ASUFC, Udine, Italy

Davide Lazzarotto

1 Division of Hematology, Azienda Sanitaria-Universitaria Friuli Centrale, ASUFC, Udine, Italy

Maddalena Peghin

3 Azienda Sanitaria-Universitaria Friuli Centrale, ASUFC, Division of Infectious Diseases, Udine, Italy

Stefano Cordella

2 Division of Hematology, University of Modena and Reggio Emilia, Dept. of Medical and Surgical Sciences, Modena, Italy

Renato Fanin

1 Division of Hematology, Azienda Sanitaria-Universitaria Friuli Centrale, ASUFC, Udine, Italy

Anna Candoni

2 Division of Hematology, University of Modena and Reggio Emilia, Dept. of Medical and Surgical Sciences, Modena, Italy